Patient and treatment characteristics
| . | No. of patients (%) . | Median (range) . |
|---|---|---|
| Sex | ||
| Male | 148 (55.4) | |
| Female | 119 (44.6) | |
| GHSG disease classification | ||
| Early favorable | 74 (27.7) | |
| Early unfavorable | 178 (66.7) | |
| IIB-advanced | 15 (5.6) | |
| Ann Arbor disease stage | ||
| IA | 32 (12) | |
| IB | 10 (3.7) | |
| IAE | 1 (0.4) | |
| IIA | 162 (60.7) | |
| IIB | 52 (19.5) | |
| IIBE | 2 (0.7) | |
| IIAE | 8 (3.0) | |
| B-symptoms | ||
| Present | 66 (24.7) | |
| Absent | 201 (75.3) | |
| ESR | ||
| Normal | 61 (22.8) | |
| Elevated | 31 (11.6) | |
| Unknown | 175 (65.5) | |
| Bulky disease | ||
| Present | 74 (27.7) | |
| Absent | 193 (72.3) | |
| Extranodal disease | ||
| Absent | 254 (95.1) | |
| Present | 13 (4.9) | |
| Chemotherapy regimens | ||
| ABVD | 239 (89.5) | |
| Other | 28 (10.5) | |
| No. of chemotherapy cycles | ||
| 0 | 1 (0.4) | |
| 2 | 18 (6.7) | |
| 3 | 5 (1.9) | |
| 4 | 108 (40.4) | |
| 5 | 10 (3.7) | |
| Received consolidation RT | ||
| Yes | 187 (70.0) | |
| No | 63 (23.6) | |
| NA | 17 (6.4) | |
| Age at diagnosis, y | 267 | 31.96 (18-95.4) |
| ESR, mm/h | 92 | 29.5 (3-107) |
| Radiation dose (Gy) | 183 | 30.6 (20-42) |
| No. of involved Ann Arbor sites | 267 | 3 (1-10) |
| . | No. of patients (%) . | Median (range) . |
|---|---|---|
| Sex | ||
| Male | 148 (55.4) | |
| Female | 119 (44.6) | |
| GHSG disease classification | ||
| Early favorable | 74 (27.7) | |
| Early unfavorable | 178 (66.7) | |
| IIB-advanced | 15 (5.6) | |
| Ann Arbor disease stage | ||
| IA | 32 (12) | |
| IB | 10 (3.7) | |
| IAE | 1 (0.4) | |
| IIA | 162 (60.7) | |
| IIB | 52 (19.5) | |
| IIBE | 2 (0.7) | |
| IIAE | 8 (3.0) | |
| B-symptoms | ||
| Present | 66 (24.7) | |
| Absent | 201 (75.3) | |
| ESR | ||
| Normal | 61 (22.8) | |
| Elevated | 31 (11.6) | |
| Unknown | 175 (65.5) | |
| Bulky disease | ||
| Present | 74 (27.7) | |
| Absent | 193 (72.3) | |
| Extranodal disease | ||
| Absent | 254 (95.1) | |
| Present | 13 (4.9) | |
| Chemotherapy regimens | ||
| ABVD | 239 (89.5) | |
| Other | 28 (10.5) | |
| No. of chemotherapy cycles | ||
| 0 | 1 (0.4) | |
| 2 | 18 (6.7) | |
| 3 | 5 (1.9) | |
| 4 | 108 (40.4) | |
| 5 | 10 (3.7) | |
| Received consolidation RT | ||
| Yes | 187 (70.0) | |
| No | 63 (23.6) | |
| NA | 17 (6.4) | |
| Age at diagnosis, y | 267 | 31.96 (18-95.4) |
| ESR, mm/h | 92 | 29.5 (3-107) |
| Radiation dose (Gy) | 183 | 30.6 (20-42) |
| No. of involved Ann Arbor sites | 267 | 3 (1-10) |
Other chemotherapy regimens besides ABVD included Adriamycin, hydroxydaunorubicin, and bleomycin or rituximab-ABVD.
ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; NA, not available; RT, radiation therapy.